

PETITION RULE PRM 35-9 (54 FR 38 239)

9888 Genesee Avenue 323
Post Office Box 28
La Jolla. California 92038-0028
(619) 457-4123

619 457-4123

BOCKE BRANCE L' VICT

November 29, 1989

Secretary of the Commission U.S. Nuclear Regulatory Commission Docketing and Service Branch, Docket # PRM-35-9 Washington, DC 20555

Dear Mr. Secretary:

I am writing to express my strong support for the Petition for Rulemaking filed by the American College of Nuclear Physicians and the Society of Nuclear Medicine. I am a practicing Nuclear Medicine physician at Scripps Memorial Hospital in La Jolla, CA. I am deeply concerned over the revised 10 CFR 35 regulations (effective April, 1987) governing the medical use of byproduct material as they significantly impact my ability to practive high-quality Nuclear Medicine and or preventing me from providing optimized care to individual patients.

The NRC should recognize that the FDA does allow, and often encourages, other clinical uses of approved drugs, and actively discourages the submission of physician-sponsored IND's that describe new indications for approved drugs. The package insert was never intended to prohibit physicians from deviating from it for other indications; on the contrary, such deviation is necessary for growth in developing new diagnostic and therapeutic procedures. In many cases, manufacturers will never go back to the FDA to revise a package insert to include a new indication because it is not required by the FDA and there is simply no economic incentive to do so.

Currently, the regulatory provisions in Part 35 (35.100, 35.200, 35.300 and 33.17 (a) (4)) do not allow practices which are legitimate and legal under the FDA regulations and State medicine and pharmacy laws. These regulations therefore inappropriately interfer with the practice of medicine, which directly contradicts the NRC's Medical Policy statement against such interference.

Finally, I would like to point out that highly restrictive NRC regulations will only jeopardize pubic health and safety: restricting access to appropriate Nuclear Medicine procedures; exposing patient to higher radiation absorbed doses from alternative legal, but non-optimal, studies; and exposing hospital personnal to higher radiation absorbed doses because of unwarranted, repetitive procedures. The NRC should not strive to construct proscriptive

Page 1 of 2 Pages

2510



9888 Genesee Avenue Post Office Box 28 La Jolla, California 92038-0028

(619) 457-4123

Page 2 of 2 Pages

regulations to cover all aspects of medicine, nor should it attempt to regulate radiopharmaceutical use. Instead, the NRC should rely on the expertise of the FDA, State Boards of Pharmacy, State Boards of Medical Quality Assurance, the Joint Commission on Accreditation of Healthcare Organizations, radiation safety committees, institutional Q/A review procedures, and most importantly, the professional judgement of physicians and pharmacists who have been well-trained to administer and prepare these materials.

Since the NRC's primary regulatory focus appears to be based on the unsubstantiated assumption that misadministration, particularly those involving diagnostic radiopharmaceuticals, pose a serious threat the public health and safety, I strongly under the NRC to pursue a comprehensive study by a reputable scientific panel, such as the National Academy of Sciences of the NCRP, to assess the radiobilogical effects of misadministrations from Nuclear Medicine diagnostic and therapeutic studies. I firmly believe that the results of such a study will demonstrate that the NRC's efforts to impose more and more stringent regulations are unnecessary and not cost-effective in relation to the extremely low health risks of these studies.

In closing, I strongly urge the NRC to adopt the ACNP/SNM Petition for Rulemaking as expeditiously as possible.

Sincerely,

man

Michael Kan, M.D., Medical Director, Scripps Memorial Hospital

MK/dd